Navigation Links
Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
Date:2/19/2008

PALO ALTO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its year-end conference call and webcast will be held on Wednesday, February 27, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth quarter and year ended December 31, 2007.

The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-398-9398 or 612-332-0530. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 910785. The archive will be available from approximately 6:30 p.m. Eastern time on February 27 through March 12, 2008.

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in clinical development for the treatment of myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Year-End Financial Release, Conference Call and Webcast
2. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
3. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
4. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
5. 3SBio Inc. Announces Change to the Board of Directors
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. MichBio Announces Annual Meeting Keynote and Pre-Meeting Workshop
8. Cadient Group Announces Recent Executive Promotions
9. Pharmion Corporation Announces 2007 Operating Results
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
11. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... 30, 2015  With over 60,000 customers across the globe, ISN improves the efficiency ... organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide ... Headquartered in Dallas, TX , ISN ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... FRANCISCO, Calif., Aug. 15, 2011 diaDexus, Inc. (OTC Bulletin ... the development and commercialization of patent-protected in vitro ... financial results for the second quarter of 2011. ... $3.8 million, representing 45% growth over total revenues of $2.6 ...
... Aug. 15, 2011 A new post-hoc sub-analysis of ... study – those identified as the "core clinical cohort" ... with aspirin) was associated with a 26 percent relative ... death, myocardial infarction or stroke, compared to treatment with ...
... SAN DIEGO, Aug. 15, 2011 NexBio announced top ... DAS181, an investigational drug for treatment and prophylaxis of ... of influenza and parainfluenza viruses, including pandemic influenza strains. ... healthy adults infected with influenza virus, treatment with DAS181 ...
Cached Biology Technology:diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 2diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 3diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 4diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Yale University have discovered that a specialized receptor, normally ... throughout the body, sensing small molecules created by microbes ... by increasing blood pressure. The finding suggests that gut ... system for maintaining a stable blood pressure. A ...
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... from Michigan State University have successfully engineered a plant with ... as well as lead to improved animal feeds. The ... Cell , the journal of the American Society of Plant ... in oil production to engineer a plant that stores lipids ...
Cached Biology News:Blood vessels 'sniff' gut microbes to regulate blood pressure 2Blood vessels 'sniff' gut microbes to regulate blood pressure 3Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2'Fat worms' inch scientists toward better biofuel production 2
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
...
5 minutes from gel band to purified DNA...
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: